PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label phase Ib multi-institution trial that evaluates the safety
profile/tolerability and preliminary anti-tumor effect of BKM120 (a PI3K inhibitor) and
endocrine therapy combination and BEZ235 (a PI3K/ mTOR inhibitor) and endocrine therapy
combination in postmenopausal patients with hormone receptor-positive metastatic breast
cancer.